

DAFTAR PUSTAKA

1. Kementerian kesehatan RI. Laporan Tahunan Program TB, Jakarta, 2023
2. Pai, M. *et al.* Tuberculosis. *Nat. Rev. Dis. Primer* **2**, 16076 (2016).
3. Badan Narkotika Nasional. Indonesia Drug Report, Jakarta, 2023.
4. Kiboi, N. G. & Nebere, S. N. Immunological Interactions of Tuberculosis with Drugs and Substance Use: A Systematic Review and Update. *J. Pulm. Respir. Med.* **06**, (2016).
5. Atif, N., Munir, M. Z. & Khan, A. H. Impact of Illicit Drug Use On Treatment Outcomes Among Tuberculosis Patients. *Value Health* **21**, S103 (2018).
6. Soomro, G. S., Jameel, N., Khalil, R., Raza, A. & Gul, T. Prevalence of Pulmonary Tuberculosis among Illicit Injecting Drug Users of Karachi, Pakistan. (2016).
7. Rennie, T. & Bates, I. Psychology and adherence of tuberculosis patients: Do illness perceptions predict poor adherence to TB management? (2015).
8. WHO. Tuberculosis (TB) Report. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>.
9. Antonucci, G., Girardi, E., Raviglione, M. C. & Ippolito, G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). *JAMA* **274**, 143–148 (1995).
10. Grenfell, P. *et al.* Tuberculosis, injecting drug use and integrated HIV-TB care: A review of the literature. *Drug Alcohol Depend.* **129**, 180–209 (2013).
11. A prospective study of the risk of tuberculosis among HIV-infected patients - PubMed. <https://pubmed.ncbi.nlm.nih.gov/8267907/>.
12. Jick, S. S., Lieberman, E. S., Rahman, M. U. & Choi, H. K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. *Arthritis Rheum.* **55**, 19–26 (2006).
13. Ugarte-Gil, C. *et al.* Diabetes Mellitus Among Pulmonary Tuberculosis Patients From 4 Tuberculosis-endemic Countries: The TANDEM Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **70**, 780–788 (2020).
14. Baker, M. A. *et al.* The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med.* **9**, 81 (2011).
15. Carmona, L. *et al.* Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum.* **52**, 1766–1772 (2005).
16. Akan, H., Arslan, O. & Akan, O. A. Tuberculosis in stem cell transplant patients. *sp. Infect.* **62**, 421–426 (2006).
17. Arslan, B. R. *et al.* Tuberculosis in liver transplant patients. *Transplantation* **51**, 301–306 (1994).



18. Muñoz, P. *et al.* Tuberculosis in heart transplant recipients. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **21**, 398–402 (1995).
19. Rao, V. G. *et al.* Tobacco smoking: a major risk factor for pulmonary tuberculosis--evidence from a cross-sectional study in central India. *Trans. R. Soc. Trop. Med. Hyg.* **108**, 474–481 (2014).
20. Bates, M. N. *et al.* Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. *Arch. Intern. Med.* **167**, 335–342 (2007).
21. Lönnroth, K., Williams, B. G., Stadlin, S., Jaramillo, E. & Dye, C. Alcohol use as a risk factor for tuberculosis – a systematic review. *BMC Public Health* **8**, 289 (2008).
22. Edwards, L. B., Livesay, V. T., Acquaviva, F. A. & Palmer, C. E. Height, weight, tuberculous infection, and tuberculous disease. *Arch. Environ. Health* **22**, 106–112 (1971).
23. Gibney, K. B. *et al.* Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **46**, 443–446 (2008).
24. Kamboj, M. & Sepkowitz, K. A. The risk of tuberculosis in patients with cancer. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **42**, 1592–1595 (2006).
25. Corbett, E. L. *et al.* HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. *AIDS Lond. Engl.* **14**, 2759–2768 (2000).
26. Hussein, M. M., Mooij, J. M. & Roujouleh, H. Tuberculosis and chronic renal disease. *Semin. Dial.* **16**, 38–44 (2003).
27. Thorn, P. A., Brookes, V. S. & Waterhouse, J. A. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. *Br. Med. J.* **1**, 603–608 (1956).
28. Inghammar, M. *et al.* COPD and the risk of tuberculosis--a population-based cohort study. *PloS One* **5**, e10138 (2010).
29. Ribeiro, F. K. C. *et al.* Genotypic and Spatial Analysis of Mycobacterium tuberculosis Transmission in a High-Incidence Urban Setting. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **61**, 758–766 (2015).
30. MacIntyre, C. R., Kendig, N., Kummer, L., Birago, S. & Graham, N. M. Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **24**, 1060–1067 (1997).
31. Cantwell, M. F., McKenna, M. T., McCray, E. & Onorato, I. M. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. *Am. J. Tr. Crit. Care Med.* **157**, 1016–1020 (1998).



nterian Hukum dan HAM Republik Indonesia. Undang Undang Nomor-
hun 2009.

33. Freeman, T. P. *et al.* Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. *Addict. Abingdon Engl.* **116**, 1000–1010 (2021).
34. Redman, M. Cocaine: What is the Crack? A Brief History of the Use of Cocaine as an Anesthetic. *Anesthesiol. Pain Med.* **1**, 95–97 (2011).
35. Han, B., Volkow, N. D., Compton, W. M. & McCance-Katz, E. F. Reported Heroin Use, Use Disorder, and Injection Among Adults in the United States, 2002-2018. *JAMA* **323**, 568–571 (2020).
36. *Drug Abuse Treatment and Rehabilitation: A Practical Planning and Implementation Guide.* (United Nations, New York, 2003).
37. Anglin, M. D., Burke, C., Perrochet, B., Stamper, E. & Dawud-Noursi, S. History of the methamphetamine problem. *J. Psychoactive Drugs* **32**, 137–141 (2000).
38. Maxwell, J. C. & Brecht, M.-L. Methamphetamine: here we go again? *Addict. Behav.* **36**, 1168–1173 (2011).
39. Badan Narkotika Nasional (BNN). Standar Pelayanan Rehabilitasi Bagi Pecandu dan Korban Penyalahgunaan Narkoba. 2020
40. Ahmed, A., Ruiz, M. J., Cohen Kadosh, K., Patton, R. & Resurrección, D. M. Khat and neurobehavioral functions: A systematic review. *PloS One* **16**, e0252900 (2021).
41. Alemu, W. G., Zeleke, T. A., Takele, W. W. & Mekonnen, S. S. Prevalence and risk factors for khat use among youth students in Ethiopia: systematic review and meta-analysis, 2018. *Ann. Gen. Psychiatry* **19**, 16 (2020).
42. Mattick, R. P., Breen, C., Kimber, J. & Davoli, M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst. Rev.* **2014**, CD002207 (2014).
43. De Aquino, J. P., Parida, S. & Sofuoglu, M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. *Clin. Drug Investig.* **41**, 425–436 (2021).
44. UNESCO. World Drug Report 2023. *United Nations : Office on Drugs and Crime* //www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.
45. Jordan, A. & Perlman, D. C. Tuberculosis Among People Who Use Drugs: Multilevel considerations for prevention , diagnosis and treatment. in *Tuberculosis: Integrated Studies for a Complex Disease* 669–696 (Springer, Stockholm, Sweden, 2023).
46. Saurer, T. B., Carrigan, K. A., Ijames, S. G. & Lysle, D. T. Suppression of al killer cell activity by morphine is mediated by the nucleus accumbens *J. Neuroimmunol.* **173**, 3–11 (2006).



47. Irwin, M. R. *et al.* Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms. *J. Pharmacol. Exp. Ther.* **320**, 507–515 (2007).
 48. Story, A., Bothamley, G. & Hayward, A. Crack cocaine and infectious tuberculosis. *Emerg. Infect. Dis.* **14**, 1466–1469 (2008).
 49. Lorenzo, P., Portolés, A., Beneit, J. V., Ronda, E. & Portolés, A. Physical dependence to morphine diminishes the interferon response in mice. *Immunopharmacology* **14**, 93–99 (1987).
 50. French, C. E. *et al.* Cannabis use and the risk of tuberculosis: a systematic review. *BMC Public Health* **19**, 1006 (2019).
 51. Al-Maweri, S. A., Warnakulasuriya, S. & Samran, A. Khat (*Catha edulis*) and its oral health effects: An updated review. *J. Investig. Clin. Dent.* **9**, (2018).
 52. McAllister, W. B. The global political economy of scheduling: the international–historical context of the Controlled Substances Act. *Drug Alcohol Depend.* **76**, 3–8 (2004).
 53. Noykhovich, E., Mookherji, S. & Roess, A. The Risk of Tuberculosis among Populations Living in Slum Settings: a Systematic Review and Meta-analysis. *J. Urban Health* **96**, 262–275 (2019).
 54. Prieto García, R., Millet, J. P., Palma, D., Barbaglia Navarro, M. G. & Gibert, C. R. Latent Tuberculosis Infection in Users of Drug Dependence Care and Follow-up Centers in Barcelona in 2017–2021: A Cross-sectional Descriptive Study. *Open Respir. Arch.* **5**, 100257 (2023).
 55. Honarvar, B. *et al.* Pulmonary and Latent Tuberculosis Screening in Opiate Drug Users: An Essential and Neglected Approach for Harm-Reduction Facilities. *J. Addict. Med.* **7**, 230–235 (2013).
 56. Oeltmann, J. E. *et al.* Tuberculosis Outbreak in Marijuana Users, Seattle, Washington, 2004. *Emerg. Infect. Dis.* **12**, 1156–1159 (2006).
 57. Scholze, A. R. *et al.* Tuberculosis among People Living on the Street and Using Alcohol, Tobacco, and Illegal Drugs: Analysis of Territories in Extreme Vulnerability and Trends in Southern Brazil. *Int. J. Environ. Res. Public Health* **19**, 7721 (2022).
 58. Story, A. *et al.* Tuberculosis in London: the importance of homelessness, problem drug use and prison. *Thorax* **62**, 667–671 (2007).
 59. Favril, L. Drug use before and during imprisonment: Drivers of continuation. *Int. J. Drug Policy* **115**, 104027 (2023).
 60. Tashkin, D. P. Effects of marijuana smoking on the lung. *Ann. Am. Thorac. Soc.* **10**, 39–47 (2013).
- Substance Use and Mental Health Indicators in the United States: Results the 2022 National Survey on Drug Use and Health. (2022).



62. Afroz, S. & Flora, M. S. Relationship between Substance Abuse and Multidrug-Resistant Tuberculosis. *Ibrahim Med. Coll. J.* **6**, 50–54 (2013).
63. McCance-Katz, E. F., Moody, D. E., Prathikanti, S., Friedland, G. & Rainey, P. M. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. *Drug Alcohol Depend.* **118**, 326–334 (2011).
64. Pontali, E. & Manga, S. Tuberculosis and Prisons. 195–201 (2021) doi:10.1007/978-3-030-66703-0_22.
65. Dara, M. *et al.* Tuberculosis control in prisons: current situation and research gaps. *Int. J. Infect. Dis.* **32**, 111–117 (2015).
66. Tavošchi, L., O’Moore, É. & Hedrich, D. Challenges and opportunities for the management of infectious diseases in Europe’s prisons: evidence-based guidance. *Lancet Infect. Dis.* **19**, e253–e258 (2019).
67. Dolan, K. *et al.* Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *The Lancet* **388**, 1089–1102 (2016).
68. Velen, K. & Charalambous, S. Tuberculosis in prisons: an unintended sentence? *Lancet Public Health* **6**, e263–e264 (2021).
69. Munro, S. A. *et al.* Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research. *PLOS Med.* **4**, e238 (2007).
70. Adilo, T. M. Determinants of TB Stigma, and its Effects on Health Care Seeking Behaviour and Treatment Adherence among TB Patients in Addis Ababa, Ethiopia: A Cross Sectional Study Design. (2017).
71. Nezenega, Z. S., Perimal-Lewis, L. & Maeder, A. J. Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review. *Int. J. Environ. Res. Public Health* **17**, 5626 (2020).
72. Knutsen, A. K. Perceptions and beliefs on tuberculosis and the influence on health seeking behaviour.
73. Pampalia, N., Waluyo, A. & Yona, S. Knowledge, stigma and health-seeking behavior of patients co-infected with HIV and tuberculosis in Jakarta. *Enferm. Clínica* **31**, S291–S295 (2021).
74. Soboka, M. *et al.* Substance use disorders and adherence to antituberculosis medications in Southwest Ethiopia: a prospective cohort study. *BMJ Open* **11**, e043050 (2021).
75. Min, J. *et al.* Understanding illness perception in pulmonary tuberculosis patients: One step towards patient-centered care. *PLoS ONE* **14**, (2019).
76. Petrie, K. J., Jago, L. A. & Devcich, D. A. The role of illness perceptions in its with medical conditions: *Curr. Opin. Psychiatry* **20**, 163–167 (2007).
77. Ibbent, E. *et al.* A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. *Psychol. Health* **30**, 1361–1385 (2015).



78. Macq, J., Solis, A. & Martinez, G. Assessing the stigma of tuberculosis. *Psychol. Health Med.* **11**, 346–352 (2006).
79. Pesut, D. P. *et al.* Illness perception in tuberculosis by implementation of the Brief Illness Perception Questionnaire – a TBNET study. *SpringerPlus* **3**, 664 (2014).
80. Basu, S. & Poole, J. The Brief Illness Perception Questionnaire. *Occup. Med. Oxf. Engl.* **66**, 419–420 (2016).
81. Husain, M. O., Dearman, S. P., Chaudhry, I. B., Rizvi, N. & Waheed, W. The relationship between anxiety, depression and illness perception in tuberculosis patients in Pakistan. *Clin. Pract. Epidemiol. Ment. Health* **4**, 4 (2008).
82. Muhammed, S., Nagla, S. & Morten, S. Illness perceptions and quality of life among tuberculosis patients in Gezira, Sudan. *Afr. Health Sci.* **15**, 385–393 (2015).
83. Ferreira, M. R. *et al.* Tuberculosis in prison and aspects associated with the diagnosis site. *J. Infect. Dev. Ctries.* **13**, 968–977 (2019).
84. Odone, A. *et al.* People- and patient-centred care for tuberculosis: models of care for tuberculosis. *Int. J. Tuberc. Lung Dis.* **22**, 133–138 (2018).
85. Biadlegne, F., Rodloff, A. C. & Sack, U. Review of the prevalence and drug resistance of tuberculosis in prisons: a hidden epidemic. *Epidemiol. Infect.* **143**, 887–900 (2015).

